DK3169315T3 - Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse - Google Patents

Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse Download PDF

Info

Publication number
DK3169315T3
DK3169315T3 DK15821947.7T DK15821947T DK3169315T3 DK 3169315 T3 DK3169315 T3 DK 3169315T3 DK 15821947 T DK15821947 T DK 15821947T DK 3169315 T3 DK3169315 T3 DK 3169315T3
Authority
DK
Denmark
Prior art keywords
liquid
dosage form
immediate release
prevent immediate
release abuse
Prior art date
Application number
DK15821947.7T
Other languages
English (en)
Inventor
Edwin R Thompson
Eric R Thompson
Nicholas R Myslinski
Steven F Kemeny
Matthew N Hart
Original Assignee
Pharmaceutical Manufacturing Res Services In
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Manufacturing Res Services In filed Critical Pharmaceutical Manufacturing Res Services In
Application granted granted Critical
Publication of DK3169315T3 publication Critical patent/DK3169315T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
DK15821947.7T 2014-07-17 2015-07-07 Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse DK3169315T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025878P 2014-07-17 2014-07-17
PCT/US2015/039336 WO2016010771A1 (en) 2014-07-17 2015-07-07 Immediate release abuse deterrent liquid fill dosage form

Publications (1)

Publication Number Publication Date
DK3169315T3 true DK3169315T3 (da) 2020-08-10

Family

ID=55073631

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15821947.7T DK3169315T3 (da) 2014-07-17 2015-07-07 Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse

Country Status (8)

Country Link
US (2) US9707184B2 (da)
EP (1) EP3169315B1 (da)
JP (2) JP6371463B2 (da)
AU (2) AU2015290098B2 (da)
CA (1) CA2955229C (da)
DK (1) DK3169315T3 (da)
ES (1) ES2809458T3 (da)
WO (1) WO2016010771A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Family Cites Families (696)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA265559A (en) 1926-11-02 F. L. Smidth And Co. Tube mill
CA264736A (en) 1926-10-05 S. Goulet William Rotary engine
GB135381A (da)
CA265145A (en) 1926-10-19 T. Thomas Horace Transmission brake
NL143131B (nl) 1964-07-11 1974-09-16 Acf Chemiefarma Nv Werkwijze voor de bereiding van antiparasitair werkzame preparaten en van actieve bestanddelen daarvoor alsmede de aldus verkregen gevormde preparaten.
CS162957B1 (da) 1972-05-24 1975-07-31
US4126684A (en) 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
JPS5584166A (en) 1978-12-20 1980-06-25 Lion Hamigaki Kk Band for spongy medicine
US4507276A (en) 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
PL133984B2 (en) 1983-02-21 1985-07-31 Method of manufacture of complex of derivatives of cellulose with polyhydric alcohol or its polymer
JPS6092214A (ja) 1983-10-26 1985-05-23 Ss Pharmaceut Co Ltd 軟カプセル充填用組成物
AU3880185A (en) 1984-02-08 1985-08-27 R.P. Scherer Corporation Acetaminophen gelatin capsule
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5155212A (en) 1986-05-21 1992-10-13 Abbott Laboratories Phencyclidine and phencyclidine metabolites assay, tracers, immunogens, antibodies and reagent kit
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US5202128A (en) 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
GB8926612D0 (en) 1989-11-24 1990-01-17 Erba Farmitalia Pharmaceutical compositions
US5141961A (en) 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
CA2146637C (en) 1992-10-09 2001-02-13 James Grigg Upson Pharmaceutical compositions and methods for treating cold symptoms
AU6086794A (en) 1993-02-18 1994-09-14 Warner-Lambert Company Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents
IL108366A (en) 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
SE9301057L (sv) 1993-03-30 1994-10-01 Pharmacia Ab Beredning med kontrollerad frisättning
US5431916A (en) 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
EP0695175A1 (en) 1993-04-30 1996-02-07 The Procter & Gamble Company Coated pharmaceutical compositions
AU6718494A (en) 1993-05-13 1994-12-12 Merck Frosst Canada Inc. 2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
JPH1133084A (ja) 1994-02-10 1999-02-09 Yamanouchi Pharmaceut Co Ltd 口腔内溶解型錠剤およびその製造方法
US5458879A (en) 1994-03-03 1995-10-17 The Procter & Gamble Company Oral vehicle compositions
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5660859A (en) 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
US5616621A (en) 1995-01-30 1997-04-01 American Home Products Corporation Taste masking liquids
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
EA199800533A1 (ru) 1995-12-07 1999-02-25 Эли Лилли Энд Компани Композиция для лечения боли
JP2000501711A (ja) 1995-12-07 2000-02-15 イーライ・リリー・アンド・カンパニー 疼痛を処置する方法
DE69722191T2 (de) 1996-03-08 2004-04-01 Nycomed Danmark Aps Dosiszusammensetzung mit modifizierter freigabe aus vielen einzelkomponenten
WO1997033566A2 (en) 1996-03-12 1997-09-18 Alza Corporation Composition and dosage form comprising opioid antagonist
AU3404997A (en) 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
DK1014941T3 (da) 1996-06-26 2009-07-27 Univ Texas Ekstruderbar farmaceutisk hot-melt-formulering
US6024980A (en) 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US5914129A (en) 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
DE69730982T2 (de) 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
US6160020A (en) 1996-12-20 2000-12-12 Mcneill-Ppc, Inc. Alkali metal and alkaline-earth metal salts of acetaminophen
HUP9903375A3 (en) 1997-03-24 2000-04-28 Lilly Co Eli Synergistic pharmaceutical compositions containing olanzapine and analgetic drugs
WO1998050075A1 (en) 1997-05-07 1998-11-12 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
EP0980247A1 (en) 1997-05-07 2000-02-23 Algos Pharmaceutical Corporation Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US20040043071A1 (en) 2002-06-21 2004-03-04 Pauletti Giovanni M. Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs
US7744916B2 (en) 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
CZ299283B6 (cs) 1997-12-22 2008-06-04 Euro-Celtique, S. A. Léková forma pro perorální podání
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
CN1296516A (zh) 1998-02-06 2001-05-23 联合碳化化学品及塑料技术公司 烯化氧聚合物组合物
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
AR014765A1 (es) 1998-03-23 2001-03-28 Gen Mills Marketing Inc Composicion de matriz comestible con textura masticable, producto comestible y masticable, composicion comestible, cobertura de alimentos y metodo para la fabricacion de productos comestibles
US6054451A (en) 1998-04-21 2000-04-25 Algos Pharmaceutical Corporation Analgesic composition and method for alleviating pain
AR020729A1 (es) 1998-10-09 2002-05-29 Gen Mills Marketing Inc Un metodo para el encapsulado de componentes sensibles en una matriz para obtener particulas discretas y estables durante su almacenamiento
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
WO2000029023A1 (en) 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with nmda-blockers for treating pain
WO2000029022A1 (en) 1998-11-12 2000-05-25 Algos Pharmaceutical Corporation Cox-2 inhibitors in combination with centrally acting analgesics
FR2787715B1 (fr) 1998-12-23 2002-05-10 Synthelabo Composition pharmaceutique comprenant un compose hypnotique ou un de ses sels pharmaceutiquement acceptables
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7060708B2 (en) 1999-03-10 2006-06-13 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
JP2003522127A (ja) 1999-07-29 2003-07-22 ロクセニ ラボラトリーズ インコーポレイテッド オピオイド徐放性製剤
IT1313579B1 (it) 1999-07-30 2002-09-09 Acraf Composizione farmaceutica liquida a base di paracetamolo.
IT1314184B1 (it) 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
HUP0203623A2 (hu) 1999-08-31 2003-02-28 Grünenthal GmbH Tramadol-szacharinátot tartalmazó, késleltetett hatású adagolási forma és alkalmazása
US6432450B1 (en) 1999-09-09 2002-08-13 Gerhard Gergely Effervescent granules with delayed effervescent effect
US6264983B1 (en) 1999-09-16 2001-07-24 Rhodia, Inc. Directly compressible, ultra fine acetaminophen compositions and process for producing same
US6572891B1 (en) 1999-10-23 2003-06-03 Alkaloid Ad Sublingual oral dosage form
ATE304870T1 (de) 1999-10-29 2005-10-15 Los Angeles Childrens Hospital Verfahren und material zur hämostase bei knochen
AU1466001A (en) 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
US20050233459A1 (en) 2003-11-26 2005-10-20 Melker Richard J Marker detection method and apparatus to monitor drug compliance
US6207674B1 (en) 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
US6608041B2 (en) 2000-02-18 2003-08-19 Milton Hammerly Analgesics combined with naturally-occurring chondroprotective agents
US20010036943A1 (en) 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
AU5956001A (en) 2000-05-05 2001-11-20 Pain Therapeutics Inc Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US20040156872A1 (en) 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
BR0111207A (pt) 2000-05-31 2003-04-01 Warner Lambert Co Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
GB0015617D0 (en) 2000-06-26 2000-08-16 Vectura Ltd Improved preparations for dermal delivery of active substances
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20040047910A1 (en) 2000-07-07 2004-03-11 Christian Beckett Suppository and composition comprising at least one polyethylene glycol
AU782523B2 (en) 2000-07-13 2005-08-04 Euro-Celtique S.A. Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
WO2002051432A1 (en) 2001-11-16 2002-07-04 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
WO2003020200A2 (en) 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
US6924273B2 (en) 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
EP1337244A4 (en) 2000-10-30 2006-01-11 Euro Celtique Sa HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US6800668B1 (en) 2001-01-19 2004-10-05 Intellipharmaceutics Corp. Syntactic deformable foam compositions and methods for making
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US20030004177A1 (en) 2001-05-11 2003-01-02 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
CA2449519A1 (en) 2001-06-08 2002-12-19 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
CA2449247A1 (en) 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
US7968119B2 (en) 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
WO2003013481A1 (en) 2001-08-03 2003-02-20 Bakulesh Mafatlal Khamar The process of manufacturing pharmaceutical composition with increased content of poorly soluble pharmaceutical ingredients
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
WO2003015531A2 (en) 2001-08-06 2003-02-27 Thomas Gruber Pharmaceutical formulation containing dye
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7375083B2 (en) 2003-09-30 2008-05-20 Shire Llc Pharmaceutical compositions for prevention of overdose or abuse
US20030068276A1 (en) 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
US20030092724A1 (en) 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
WO2003024429A1 (en) 2001-09-21 2003-03-27 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
CA2459976A1 (en) 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Opioid formulations having reduced potential for abuse
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
KR100974842B1 (ko) 2001-10-18 2010-08-11 넥타르 테라퓨틱스 아편양 길항제의 중합체 공액
KR20040084891A (ko) 2001-10-22 2004-10-06 타로 파르마수티컬 인더스트리즈, 엘티디. 미각 차폐용 유출-저항성 제제
US20030235618A1 (en) 2001-10-22 2003-12-25 Taro Pharmaceutical Industries Ltd. Taste masking spill-resistant formulation
US20050143471A1 (en) 2001-10-22 2005-06-30 Shen Gao Taste masking spill-resistant formulation
US6771370B2 (en) 2001-10-22 2004-08-03 The Texas A&M University System Characterizing powders using frequency-domain photon migration
WO2003039561A1 (en) 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
JP2005520797A (ja) 2001-12-14 2005-07-14 メルク フロスト カナダ アンド カンパニー プロスタグランジン受容体リガンドとしてのキノリノン
US20070167853A1 (en) 2002-01-22 2007-07-19 Melker Richard J System and method for monitoring health using exhaled breath
US6713470B2 (en) 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
JP2005519923A (ja) 2002-02-04 2005-07-07 ファルマシア・コーポレーション シクロオキシゲナーゼ−２選択的阻害剤ならびに風邪および咳止め薬の組み合わせを用いる風邪および咳の治療ならびにそれらの組成物
EP1471890B1 (en) 2002-02-07 2006-09-27 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
DK1480624T3 (da) 2002-02-07 2007-03-12 Pharmacia Corp Farmaceutisk tablet
GB0203276D0 (en) 2002-02-12 2002-03-27 Novartis Ag Organic compounds
US20060177381A1 (en) 2002-02-15 2006-08-10 Howard Brooks-Korn Opiopathies
NZ535456A (en) 2002-02-21 2006-08-31 Biovail Lab Int Srl Modified release formulations of at least one form of tramadol for oral administration
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US6753009B2 (en) 2002-03-13 2004-06-22 Mcneil-Ppc, Inc. Soft tablet containing high molecular weight polyethylene oxide
DK1578350T3 (da) 2002-03-26 2009-08-10 Euro Celtique Sa Sammensætninger med gel-coating med depotvirkning
DE10215131A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
NZ535286A (en) 2002-04-05 2007-07-27 Euro Celtique Sa Matrix for sustained, invariant and independent release of active compounds
DE10215067A1 (de) 2002-04-05 2003-10-16 Euro Celtique Sa Lagerstabiles pharmazeutisches Präparat, das Oxycodon und Naloxon umfasst
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
EP1496931A4 (en) 2002-04-19 2009-07-01 Bristol Myers Squibb Co METHODS OF TREATING AUTOIMMUNE DISEASE USING SOLUBLE CTLA4 MOLECULE AND ARMM OR NSAID
US20030199496A1 (en) 2002-04-22 2003-10-23 Simon David Lew Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
US20030199439A1 (en) 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
FR2838647B1 (fr) 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
US20030203027A1 (en) 2002-04-26 2003-10-30 Ethicon, Inc. Coating technique for deposition of drug substance on a substrate
US20040009172A1 (en) 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2003092648A1 (en) 2002-04-29 2003-11-13 Alza Corporation Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US7485298B2 (en) 2002-05-23 2009-02-03 Michael Powell Diagnosis and treatment of human dormancy-related sequellae
EP1513497A2 (en) 2002-05-31 2005-03-16 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050266072A1 (en) 2002-08-15 2005-12-01 Euro-Celtique S.A. Pharmaceutical compositions
US20050152905A1 (en) 2002-08-22 2005-07-14 Omoigui Osemwota S. Method of biochemical treatment of persistent pain
US20050020613A1 (en) 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
WO2004026262A2 (en) 2002-09-23 2004-04-01 Verion, Inc. Abuse-resistant pharmaceutical compositions
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CA2503381A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
US20070292461A1 (en) 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1603593A4 (en) 2002-11-15 2007-08-01 Branded Products For The Futur PHARMACEUTICAL COMPOSITION
US20040110781A1 (en) 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
EP2959893A1 (en) 2002-12-13 2015-12-30 DURECT Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
EP1572164A2 (en) 2002-12-18 2005-09-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
CA2514879C (en) 2003-01-03 2014-09-16 Shire Laboratories Inc. Two or more enteric materials to regulate drug release
US7763043B2 (en) 2003-01-09 2010-07-27 Boston Scientific Scimed, Inc. Dilatation catheter with enhanced distal end for crossing occluded lesions
US20040259948A1 (en) 2003-01-10 2004-12-23 Peter Tontonoz Reciprocal regulation of inflammation and lipid metabolism by liver X receptors
MXPA05007771A (es) 2003-01-22 2005-09-30 Pfizer Prod Inc Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
WO2004064807A1 (en) 2003-01-23 2004-08-05 Amorepacific Corporation Sustained-release preparations and method for producing the same
FR2850576B1 (fr) 2003-02-05 2007-03-23 Ethypharm Sa Composition comprenant un melange de principes actifs, et procede de preparation
EP1605916A4 (en) 2003-02-12 2012-02-22 R & P Korea Co Ltd SOLUBENT SOLVENT SYSTEM WITH SOLUBLE PEEL WITH IMPROVED ELUTION RATE
WO2004075832A2 (en) 2003-02-27 2004-09-10 Lucas John M Methods and compositions for the treatment of chronic pain using dhea and derivatives thereof
US20050004098A1 (en) 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
PT1608407E (pt) 2003-03-20 2006-12-29 Pharmacia Corp Formulação dispersível de um agente anti-inflamatório
ES2570454T3 (es) 2003-03-26 2016-05-18 Egalet Ltd Sistema de liberación controlada de morfina
WO2004100857A2 (en) 2003-05-07 2004-11-25 Akina, Inc. Highly plastic granules for making fast melting tablets
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
WO2004108163A1 (ja) 2003-06-04 2004-12-16 Shionogi & Co., Ltd. 低帯電性粉末の製造方法
WO2005000331A2 (en) 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
WO2005000237A2 (en) 2003-06-25 2005-01-06 University Of Tennessee Research Foundation Granules containing biologically active substances
US20060165790A1 (en) 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20070059346A1 (en) 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
US20050074425A1 (en) 2003-07-02 2005-04-07 Polycord, Inc. Method for delivering polymerized therapeutic agent compositions and compositions thereof
JP5296314B2 (ja) 2003-07-17 2013-09-25 バナー ファーマキャップス，インコーポレイティド 制御放出製剤
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20050059023A1 (en) 2003-09-16 2005-03-17 Cantor Thomas L. Methods and kits for monitoring resistance to therapeutic agents
CA2537336C (en) 2003-09-17 2013-02-26 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs
AU2004277898B2 (en) 2003-09-25 2009-04-02 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
EP2298303A1 (en) 2003-09-25 2011-03-23 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
US20080031901A1 (en) 2004-09-24 2008-02-07 Abbott Laboratories Sustained release monoeximic formulations of opioid and nonopioid analgesics
CA2540056C (en) 2003-09-26 2015-03-24 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
US20070259033A1 (en) 2003-09-26 2007-11-08 Evangeline Cruz Controlled release formulations exhibiting an ascending rate of release
WO2005038049A2 (en) 2003-10-06 2005-04-28 Heinrich Guenther System and method for optimizing drug therapy
US20050245557A1 (en) 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
US20060009478A1 (en) 2003-10-15 2006-01-12 Nadav Friedmann Methods for the treatment of back pain
CN101005829A (zh) 2003-10-21 2007-07-25 艾克塔维斯集团公司 喹硫平制剂
AU2003303744A1 (en) 2003-10-31 2005-06-17 Elan Pharma International Ltd. Novel nimesulide compositions
WO2005046727A2 (en) 2003-11-12 2005-05-26 Ranbaxy Laboratories Limited Ibuprofen-containing soft gelatin capsules
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20090124697A1 (en) 2003-12-16 2009-05-14 United Therapeutics Corporation Inhalation formulations of treprostinil
CA2549724C (en) 2003-12-16 2014-02-11 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
EP1703894A1 (en) 2003-12-23 2006-09-27 ALZA Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
WO2005063219A2 (en) 2003-12-23 2005-07-14 Ranbaxy Laboratories Limited Ibuprofen-containing soft gelatin capsules
WO2005070465A2 (en) 2004-01-14 2005-08-04 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005092306A1 (en) 2004-03-11 2005-10-06 The General Hospital Corporation Methods and compositions for modulating opioid tolerance and chronic pain
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
ES2244326B1 (es) 2004-04-05 2007-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de substancias activas.
US20050226929A1 (en) 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
GB0408308D0 (en) 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
EP1740179A1 (en) 2004-04-20 2007-01-10 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist
GB0408854D0 (en) 2004-04-21 2004-05-26 Univ York Separating method
WO2005107467A2 (en) 2004-05-03 2005-11-17 Descartes Therapeutics, Inc. Compositions including opioids and methods of their use in treating pain
US20050265955A1 (en) 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20080317849A1 (en) 2004-06-17 2008-12-25 Stephan Christgau Method for Improving the Medical Treatment of Pain
CA2570389A1 (en) 2004-06-17 2005-12-29 Osteologix A/S Treatments comprising strontium for rheumatic and arthritic diseases and pain
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1765305A4 (en) 2004-07-09 2008-06-04 Drugtech Corp REGULATED PHASE COMPOSITION TECHNOLOGY USED AS ENHANCED MEDICATION PROTECTION METHOD
US20060039865A1 (en) 2004-07-26 2006-02-23 Preston David M Pharmaceutical compositions and methods for the prevention of drug misuse
US20060024368A1 (en) 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
US20070003622A1 (en) 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
KR20130048793A (ko) 2004-08-12 2013-05-10 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용하여 위장관계의 운동성을 촉진하는 방법
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
EP1789028A2 (en) 2004-08-24 2007-05-30 Neuromolecular Pharmaceuticals Inc Compositions for treating nociceptive pain
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
WO2006030402A2 (en) 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Dual compartment osmotic delivery device
US20060062734A1 (en) 2004-09-20 2006-03-23 Melker Richard J Methods and systems for preventing diversion of prescription drugs
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US20060067971A1 (en) 2004-09-27 2006-03-30 Story Brooks J Bone void filler
US20060074422A1 (en) 2004-09-27 2006-04-06 Story Brooks J Suture anchor and void filler combination
KR101341359B1 (ko) 2004-10-01 2013-12-13 램스코르 인코포레이티드 편리하게 이식가능한 서방형 약물 조성물
AU2005294382A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
WO2006044645A2 (en) 2004-10-13 2006-04-27 Adolor Corporation Sulfamoyl benzamides and methods of their use
WO2006046114A2 (en) 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Osmotic dosage forms providing ascending drug release, and processes for their preparation
AU2005302452B2 (en) 2004-11-01 2010-12-09 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in Amyotrophic Lateral Sclerosis
US20060099254A1 (en) 2004-11-02 2006-05-11 Desai Divyakant S Sustained release drug delivery system and method
JP2006150061A (ja) 2004-11-04 2006-06-15 Nec Corp ドラッグデリバリシステム及びそれに用いる薬剤カプセル並びに送信機
KR20070086334A (ko) 2004-11-16 2007-08-27 리머릭 뉴로사이언스즈, 인크. 통증을 치료하기 위한 방법 및 조성물
US20070087977A1 (en) 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
FR2878161B1 (fr) 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
US20070231268A1 (en) 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en) 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060177380A1 (en) 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2878158B1 (fr) 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
US8574626B2 (en) 2004-12-03 2013-11-05 Osmotica Kereskedelmi és Szolgáltató KFT Osmotic device containing amantadine and an osmotic salt
EP1833467B1 (en) 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006075123A1 (en) 2005-01-14 2006-07-20 Camurus Ab Topical bioadhesive formulations
ATE462409T1 (de) 2005-01-14 2010-04-15 Camurus Ab Topische bioadhäsive formulierungen
FR2881652B1 (fr) 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
CA2601969A1 (en) 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
RU2007132865A (ru) 2005-03-01 2009-03-10 Пфайзер Лимитед (GB) Применение ингибиторов pde7 для лечения невропатической боли
US20060205752A1 (en) 2005-03-14 2006-09-14 Keith Whitehead Stabilized hydrocodone pharmaceutical compositions with ethylenediaminetetraacetic acid
US20060210613A1 (en) 2005-03-15 2006-09-21 Carliss Richard D Therapeutic wound care product
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
JP2008534564A (ja) 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 痛みの治療に有用な新しい製薬組成物
WO2006105205A1 (en) 2005-03-29 2006-10-05 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
WO2006103551A1 (en) 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Controlled release formulations of oxycodone
GB0506982D0 (en) 2005-04-06 2005-05-11 Mw Encap Ltd Abuse resistant capsules
BRPI0610509A2 (pt) 2005-04-22 2010-06-29 Wyeth Corp tratamento de dependência a drogas
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1881819A1 (en) 2005-05-10 2008-01-30 Novartis AG Extrusion process for making compositions with poorly compressible therapeutic compounds
US20060263429A1 (en) 2005-05-20 2006-11-23 Hengsheng Feng Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof
BRPI0611075A2 (pt) 2005-06-03 2010-08-03 Elan Pharma Int Ltd formulações de acetaminofeno em nanopartìcula
US20090143761A1 (en) 2005-06-03 2009-06-04 Transdermal Patents Company, Llc Agent delivery system and uses of same
WO2006138278A1 (en) 2005-06-13 2006-12-28 Paul Rosenberg Emetic embedded capsule
WO2006133733A1 (en) 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
US9060950B2 (en) 2005-06-13 2015-06-23 Paul H. Rosenberg, Proximate Concepts, LLC. Emetic embedded capsule
WO2007013975A2 (en) 2005-07-20 2007-02-01 Pharmorx Inc. Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications
WO2007021970A2 (en) 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof
MX2008002512A (es) 2005-08-26 2008-04-03 Bpsi Holdings Inc Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
US8343546B2 (en) 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
KR100708713B1 (ko) 2005-09-24 2007-04-17 삼성에스디아이 주식회사 나노복합체, 나노복합 전해질막 및 이를 이용한 연료전지
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007050631A2 (en) 2005-10-25 2007-05-03 Cima Labs Inc. Dosage form with coated active
US8333989B2 (en) 2005-10-26 2012-12-18 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US20090082466A1 (en) 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
WO2007056142A2 (en) 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Methods of preventing the serotonin syndrome and compositions for use therefor
WO2008134071A1 (en) 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
WO2007132293A2 (en) 2005-11-10 2007-11-22 Circ Pharma Research And Development Limited Once-daily administration of central nervous system drugs
US7544676B2 (en) 2005-11-10 2009-06-09 Adolor Corporation Sulfamoyl benzamides and methods of their use
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2892937B1 (fr) 2005-11-10 2013-04-05 Flamel Tech Sa Forme pharmaceutique orale microparticulaire anti-mesusage
US20070134493A1 (en) 2005-12-08 2007-06-14 Kanji Meghpara Compositions and capsules with stable hydrophilic layers
US9522188B2 (en) 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
WO2007072503A2 (en) 2005-12-21 2007-06-28 Panacea Biotec Ltd. Combinations for managing inflammation and associated disorders
TW200734334A (en) 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
US20100172989A1 (en) 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
BRPI0706753A2 (pt) 2006-01-21 2011-04-05 Abbott Gmbh & Co Kg forma de dosagem e método para a distribuição de fármacos de abuso
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2007090091A2 (en) 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US8163018B2 (en) 2006-02-14 2012-04-24 Warsaw Orthopedic, Inc. Treatment of the vertebral column
GB0603008D0 (en) 2006-02-14 2006-03-29 Portela & Ca Sa Method
US20070213718A1 (en) 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Treatment of the vertebral column
US20070213717A1 (en) 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Biological fusion in the vertebral column
FR2897267A1 (fr) 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
US8940796B2 (en) 2006-02-21 2015-01-27 Wyeth Llc Phenylephrine liquid formulations
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
JP2009528382A (ja) 2006-03-01 2009-08-06 トリストラータ・インコーポレイテッド タール応答性皮膚疾患の局所治療のための組成物及び方法
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US20070207200A1 (en) 2006-03-06 2007-09-06 Pozen Inc. Dosage forms for administering combinations of drugs
US20080069889A1 (en) 2006-03-07 2008-03-20 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
US20070212417A1 (en) 2006-03-07 2007-09-13 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
WO2007106550A2 (en) 2006-03-15 2007-09-20 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
CA2645855C (en) 2006-03-16 2015-02-03 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
KR20090007608A (ko) 2006-04-24 2009-01-19 파나세아 바이오테크 리미티드 니메술리드를 포함하는 새로운 형태의 저복용 약학조성물 및 이의 조제 및 사용방법
US20070254027A1 (en) 2006-04-28 2007-11-01 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
AU2007249947B2 (en) 2006-05-09 2013-03-21 SpecGx LLC Zero-order modified release solid dosage forms
WO2007128884A1 (en) 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
CN101522174A (zh) 2006-05-10 2009-09-02 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US9023400B2 (en) 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
FR2901478B1 (fr) 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US20070292508A1 (en) 2006-06-05 2007-12-20 Balchem Corporation Orally disintegrating dosage forms
US20070281016A1 (en) 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20070281017A1 (en) 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
AU2007261098A1 (en) 2006-06-19 2007-12-27 Mcneil-Ppc, Inc. Enteric coated particles containing an active ingredient
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
EP2032124A1 (en) 2006-06-27 2009-03-11 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
US20080014274A1 (en) 2006-07-14 2008-01-17 Wyeth Enhanced stability phenylephrine liquid compositions
EP2043613A1 (en) 2006-07-14 2009-04-08 Fmc Corporation Solid form
US8765178B2 (en) 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20080075771A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
US9005652B2 (en) 2006-07-25 2015-04-14 Wyeth Chewable tablet containing phenylephrine
WO2008013416A1 (en) 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
US20080026062A1 (en) 2006-07-31 2008-01-31 Isaac Farr Pharmaceutical compositions including nano-sized active agent
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
WO2008015221A2 (en) 2006-08-04 2008-02-07 Ethypharm Multilayer orally disintegrating tablet
US8465776B2 (en) 2006-08-04 2013-06-18 Ethypharm Granule and orally disintegrating tablet comprising oxycodone
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008027442A2 (en) 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
US20080057122A1 (en) 2006-08-31 2008-03-06 Aaipharma Inc. Acetaminophen pharmaceutical compositions
JP5513113B2 (ja) 2006-08-31 2014-06-04 アプタリス ファーマテック，インコーポレイテッド 弱塩基性薬剤の固溶体を含む薬剤送達システム
WO2008033351A2 (en) 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
KR20080026754A (ko) 2006-09-21 2008-03-26 주식회사 삼양사 생물학적 활성성분을 함유하는 방출 제어형 입자, 및 이의제조방법
DE102006044694A1 (de) 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
AU2007305271A1 (en) 2006-09-29 2008-04-10 Monosol Rx Llc Film embedded packaging and method of making same
US20080085312A1 (en) 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
EP2124556B1 (en) 2006-10-09 2014-09-03 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2008070268A2 (en) 2006-10-09 2008-06-12 Charleston Laboratories, Inc. Pharmaceutical compositions
US20080085304A1 (en) 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations
ES2651444T3 (es) 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
SI1940366T1 (sl) 2006-10-24 2009-08-31 Helsinn Healthcare Sa Mehke kapsule, ki obsegajo palonosetron hidroklorid, z izboljšano stabilnostjo in biorazpoložljivostjo
US20080102123A1 (en) 2006-10-27 2008-05-01 Schachter Deborah M Self-gelling tunable drug delivery system
CA2667259A1 (en) 2006-11-07 2008-05-15 Nektar Therapeutics Al, Corporation Dosage forms and co-administration of an opioid agonist and an opioid antagonist
US20080293695A1 (en) 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
RU2500685C2 (ru) 2006-11-10 2013-12-10 Кара Терапеутикс, Инк Синтетические пептидные амиды
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
WO2008063625A2 (en) 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
CA2670303A1 (en) 2006-11-22 2008-11-13 Progenics Pharmaceuticals, Inc. (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
AU2007325315A1 (en) 2006-11-28 2008-06-05 Kalypsys Inc Heterocyclic modulators of TGR5
US20080132751A1 (en) 2006-11-30 2008-06-05 Betazone Laboratories, Inc. Compositions and methods for treatment of pain
US8470361B2 (en) 2006-12-04 2013-06-25 Orexo Ab Non-abusable pharmaceutical composition comprising opioids
CA2930487A1 (en) 2007-01-16 2008-07-24 Egalet Ltd. Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i)mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008097976A1 (en) 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
EP2650303A1 (en) 2007-02-26 2013-10-16 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of heart failure and other disorders
CN101674827A (zh) 2007-03-02 2010-03-17 先灵公司 苯并咪唑衍生物及其使用方法
DE602007002154D1 (de) 2007-03-02 2009-10-08 Flamek Corp Oue Analgesische Zusammensetzung von topisch angewendeten, nichtsteroiden und entzündungshemmenden Arzneimitteln und Opioiden
MX2009009379A (es) 2007-03-02 2009-09-14 Amgen Inc Metodos y composiciones para tratar enfermedades tumorales.
TW200840571A (en) 2007-03-02 2008-10-16 Schering Corp Piperidine derivatives and methods of use thereof
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US20080226702A1 (en) 2007-03-16 2008-09-18 Endo Pharmaceuticals, Inc. Transdermal Delivery Form Disposal Systems and Methods
CL2008000838A1 (es) 2007-03-23 2008-10-10 Neuraxon Inc Compuestos derivados de quinolina y tetrahidroquinolina, con actividad inhibidora nos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un dolor de cabeza tal como migrana, dolor cronico, desordenes del sistema nervios
US20100080829A1 (en) 2007-04-11 2010-04-01 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
EP1980245A1 (en) 2007-04-11 2008-10-15 Cephalon France Bilayer lyophilized pharmaceutical compositions and methods of making and using same
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US20080286211A1 (en) 2007-04-27 2008-11-20 Barker Nicholas P Using mucin glycoproteins in combination with therapeutic agents to treat epithelial lesions and disorders of impaired mucin function
AU2008245550B2 (en) 2007-04-27 2013-10-10 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
EP2073798A2 (en) 2007-05-01 2009-07-01 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
DE102007021549A1 (de) 2007-05-08 2008-11-13 Novosis Ag Transdermales therapeutisches System enthaltend mindestens zwei Opioide
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286344A1 (en) 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
WO2008140461A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
US20080292683A1 (en) 2007-05-24 2008-11-27 Monosolrx, Llc. Film shreds and delivery system incorporating same
EP2167048B1 (en) 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US20100210604A1 (en) 2007-06-13 2010-08-19 Meythaler Jay M Zwitterion solution for low-volume therapeutic delivery
WO2008155620A1 (en) 2007-06-20 2008-12-24 Develco Pharma Schweiz Ag Dosage form containing dispersible matrix of sustained release granules
WO2009002299A1 (en) 2007-06-22 2008-12-31 Gluconova Llc Method for treating warm-blooded vertebrates with halide-free glucosamine-acidic drug complexes
US20090004281A1 (en) 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
US20090004285A1 (en) 2007-06-29 2009-01-01 Liangping Yu Stable non-disintegrating dosage forms and method of making same
JP2010532358A (ja) 2007-07-01 2010-10-07 ピーター ハバウシ，ジョセフ 咀嚼可能外層を有する配合剤
KR20100055431A (ko) 2007-07-20 2010-05-26 애보트 게엠베하 운트 콤파니 카게 비오피오이드 및 한정된 오피오이드 진통제의 제형
US20090028873A1 (en) 2007-07-27 2009-01-29 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
AU2008283903B2 (en) 2007-08-06 2014-01-16 Biotie Therapies, Inc Methods for treating dependence
EP2187873B1 (en) 2007-08-13 2018-07-25 Abuse Deterrent Pharmaceutical Llc Abuse resistant drugs, method of use and method of making
US20090105124A1 (en) 2007-08-23 2009-04-23 Kalypsys, Inc. Heterocyclic modulators of tgr5
US8377479B2 (en) 2007-09-03 2013-02-19 Nanotherapeutics, Inc. Compositions and methods for delivery of poorly soluble drugs
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
RU2010115255A (ru) 2007-09-17 2011-10-27 МакНЕЙЛ-ППС, ИНК. (US) Составы для нанесения покрытия погружением, содержащие сополимер поливинилового спирта и полиэтиленгликоля и камедь
JP5204847B2 (ja) 2007-09-21 2013-06-05 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング エタノールの影響に対して耐性を有するｐｈ依存性制御放出医薬オピオイド組成物
US20090087483A1 (en) 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
MX2010003546A (es) 2007-10-01 2010-04-30 Basf Se Mezcla rodenticida.
US20090110724A1 (en) 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of pain
WO2009066146A2 (en) 2007-11-19 2009-05-28 Cadila Pharmaceuticals Ltd. Stable solutions of sparingly soluble actives
WO2009073686A1 (en) 2007-12-03 2009-06-11 Trans Dermal Patents Company, Llc Agent delivery system and uses of the same
JP2011506318A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 経口医薬製剤
CN101951767A (zh) 2007-12-10 2011-01-19 欧兰德股份有限公司 包含苯海拉明的口服崩解片剂
AU2008338207A1 (en) 2007-12-17 2009-06-25 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
EP2240018B1 (en) 2008-01-04 2016-05-25 Schabar Research Associates LLC Composition comprising an analgesic and an antihistamine
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
BRPI0905707B1 (pt) 2008-01-18 2024-02-27 Dow Global Technologies Inc Método para aumentar a solubilidade aquosa de um composto ativo e composição compreendendo um composto ativo
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
MX2010008420A (es) 2008-02-01 2012-09-19 Abbott Lab Hidrocodona acetaminofen de liberacion extendida y metodos relacionados y sus usos.
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US8088150B2 (en) 2008-02-04 2012-01-03 Aleeva Medical Inc. Device for disc shunt implantation and peri-shunt injection
KR101094231B1 (ko) 2008-02-18 2011-12-14 하나제약 주식회사 서방성 고형 제제 및 그의 제조방법
CN107296957A (zh) 2008-03-04 2017-10-27 梯瓦制药国际有限责任公司 治疗慢性疼痛的方法
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
AU2009224254A1 (en) 2008-03-11 2009-09-17 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
BRPI0908596A2 (pt) 2008-03-21 2015-09-15 Mylan Pharmaceuticals Inc formulação e composição farmacêutica de liberação prolongada
WO2009120889A2 (en) 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
WO2009118764A1 (en) 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
EP2106799A1 (en) 2008-03-31 2009-10-07 OWEN Holding LTD Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
JP5651291B2 (ja) 2008-04-11 2015-01-07 株式会社センカファーマシー ポリエチレングリコールの誘導体およびその中間体の製造方法
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
US8420114B2 (en) 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8524267B2 (en) 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
ES2563061T3 (es) 2008-04-28 2016-03-10 Zogenix, Inc. Nuevas formulaciones para el tratamiento de la migraña
MX2010012132A (es) 2008-05-05 2010-12-06 Euro Celtique Sa Gel de oxicodona.
KR20110004425A (ko) 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
CA2724877C (en) 2008-05-20 2016-09-13 Neurogesx, Inc. Water-soluble acetaminophen analogs
US20110263545A1 (en) 2008-05-20 2011-10-27 Naweed Muhammad Hepatoprotectant acetaminophen mutual prodrugs
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
ZA200903858B (en) 2008-06-19 2013-10-30 Univ Of Witwatesrand Johannesburg Pharmaceutical dosage form
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
US20100003322A1 (en) 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
AU2009281537A1 (en) 2008-08-14 2011-06-30 Bioneer A/S Coated tablets with a remaining degradation surface over the time
US20110195116A1 (en) 2008-08-19 2011-08-11 Adcock Ingram Healthcare Pty Limited Rate modulated delivery of drugs from a composite delivery system
US20100076074A1 (en) 2008-08-26 2010-03-25 Auspex Pharmaceuticals, Inc. Carbamate reducers of skeletal muscle tension
JP5345813B2 (ja) 2008-08-28 2013-11-20 テイカ製薬株式会社 オキシコドン経皮吸収医薬組成物、医薬組成物貯蔵ユニットおよびこれを利用する経皮吸収製剤
US8067243B2 (en) 2008-09-03 2011-11-29 Oregon Medical Laboratories Methods and systems for analyzing medication levels in a sample
KR101660996B1 (ko) 2008-09-16 2016-09-28 넥타르 테라퓨틱스 남용에 대한 낮은 잠재성을 갖는 페길화 오피오이드
NZ601200A (en) 2008-09-18 2014-02-28 Purdue Pharma Lp Pharmaceutical dosage forms comprising poly(epsilon-caprolactone)
CN102164589A (zh) 2008-09-24 2011-08-24 赢创罗姆有限公司 耐受乙醇影响的非阿片类药物的pH依赖性受控释放的药物组合物
KR20110071008A (ko) 2008-10-14 2011-06-27 맥닐 에이비 다중 부분 경구내 투여량 형태 및 그의 용도
WO2010044842A1 (en) 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
US20100098746A1 (en) 2008-10-20 2010-04-22 Warsaw Orthopedic, Inc. Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
RU2599846C2 (ru) 2008-10-30 2016-10-20 Грюненталь Гмбх Новые и эффективные лекарственые формы тапентадола
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US20100143486A1 (en) 2008-12-10 2010-06-10 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US20100266682A1 (en) 2008-12-10 2010-10-21 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
WO2010069050A1 (en) 2008-12-16 2010-06-24 Labopharm Inc. Misuse preventative, controlled release formulation
AU2009332963B2 (en) 2008-12-31 2015-02-05 Upsher-Smith Laboratories, Llc Opioid-containing oral pharmaceutical compositions and methods
US20100173013A1 (en) 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
EP2700400A1 (en) 2009-01-26 2014-02-26 Egalet Ltd. Controlled release formulation with continuous efficacy
JP5408703B2 (ja) 2009-01-30 2014-02-05 国立大学法人 千葉大学 薬剤及びその製造方法
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
US8603526B2 (en) 2009-02-06 2013-12-10 Egalet Ltd. Pharmaceutical compositions resistant to abuse
US20110311626A1 (en) 2009-02-23 2011-12-22 Gopi Venkatesh Controlled release compositions comprising anti-cholinergic drugs
WO2010100414A1 (en) 2009-03-04 2010-09-10 Orexo Ab Abuse resistant formulation
EP2405901A1 (en) 2009-03-09 2012-01-18 Council of Scientific & Industrial Research Pulsatile release composition of therapeutic agent
WO2010103365A2 (en) 2009-03-09 2010-09-16 Council Of Scientific & Industrial Research Sustained release composition of therapeutic agent
JP5886632B2 (ja) 2009-03-10 2016-03-16 ユーロ−セルティーク エス．エイ． オキシコドンおよびナロキソンを含む即時放出医薬組成物
KR20120003436A (ko) 2009-03-18 2012-01-10 에보니크 룀 게엠베하 중합체 혼합물 및 부형제를 포함하는 코팅을 이용하는, 에탄올의 영향에 대한 내성을 갖는 제어 방출 제약 조성물
CN102355893A (zh) 2009-03-18 2012-02-15 赢创罗姆有限公司 采用含有中性乙烯基聚合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
RU2589823C2 (ru) 2009-04-09 2016-07-10 Алкермес Фарма Айэленд Лимитед Композиция для доставки лекарственных средств
EP2419139A2 (en) 2009-04-17 2012-02-22 Axxia Pharmaceuticals, Llc Polymeric drug delivery systems and processes for producing such systems
WO2010123999A2 (en) 2009-04-21 2010-10-28 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
WO2010124089A2 (en) 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
KR101752014B1 (ko) 2009-05-01 2017-06-28 아데어 파마슈티컬스 인코포레이티드 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
US20100291201A1 (en) 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
EP2432535B1 (en) 2009-05-18 2017-09-20 Adamis Pharmaceuticals Corporation Dry powder inhalers
WO2010138441A1 (en) 2009-05-28 2010-12-02 Aptapharma, Inc. Multilayer oral tablets containing a non-steroidal anti-inflammatory drug and/or acetaminophen
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
WO2010141596A2 (en) 2009-06-02 2010-12-09 Marquette University Chemical proteomic assay for optimizing drug binding to target proteins
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
WO2010150930A1 (ko) 2009-06-25 2010-12-29 (주)벡스코아 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
SG10201408480RA (en) 2009-06-25 2015-02-27 Crealta Pharmaceuticals Llc Methods for preventing or predicting infusion reactions or antibody-mediated loss of response, by monitoring serum uric acid levels during pegylated uricase therapy
KR101074271B1 (ko) 2009-06-25 2011-10-17 (주)차바이오앤디오스텍 불쾌한 맛을 효과적으로 은폐한 경구용 속용 필름
WO2010151333A1 (en) 2009-06-25 2010-12-29 Certusview Technologies, Llc Locating equipment for and methods of simulating locate operations for training and/or skills evaluation
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
EP3311667A1 (en) 2009-07-08 2018-04-25 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2011008298A2 (en) 2009-07-16 2011-01-20 Nectid, Inc. Novel axomadol dosage forms
MX2012000980A (es) 2009-07-21 2012-06-12 Nektar Therapeutics Conjugados de agonistas de oligómeros-opioides.
CN102639118B (zh) 2009-07-22 2015-07-29 格吕伦塔尔有限公司 氧化稳定的抗干扰剂型
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
PL3061821T3 (pl) 2009-07-22 2020-01-31 PureTech Health LLC Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego
MX343925B (es) 2009-07-31 2016-11-29 Ascendis Pharma As Hidrogeles biodegradables insolubles en agua a base de polietilenglicol.
KR20120059582A (ko) 2009-08-31 2012-06-08 데포메드 인코퍼레이티드 아세트아미노펜의 속방성 및 서방성을 위한 위 체류 약제학적 조성물
WO2011039768A2 (en) 2009-09-17 2011-04-07 Cadila Healthcare Limited Pharmaceutical compositions for reducing alcohol-induced dose dumping
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
FR2951378B1 (fr) 2009-10-16 2012-06-01 Flamel Tech Sa Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee
US20110104272A1 (en) 2009-11-05 2011-05-05 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
BR112012012999A2 (pt) 2009-11-30 2019-04-02 Aptalis Pharmatech Inc Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt)
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
WO2011066980A2 (en) 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
AU2010339882B2 (en) 2009-12-17 2016-10-27 Cima Labs Inc. Abuse-resistant formulations
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
CA2785056A1 (en) 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
WO2011079074A1 (en) 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20130023553A1 (en) 2010-01-12 2013-01-24 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
EP2359812A1 (en) 2010-01-18 2011-08-24 Cephalon France Oral lyophilised compositions
US20110195989A1 (en) 2010-02-09 2011-08-11 Rudnic Edward M Controlled Release Formulations of Opioids
US20130022646A1 (en) 2010-02-09 2013-01-24 Rudnic Edward M Controlled Release Formulations of Opioids
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
US20110195403A1 (en) 2010-02-10 2011-08-11 Selinfreund Richard H Systems and methods for fertility analysis
US20110195520A1 (en) 2010-02-11 2011-08-11 Ameritox, Ltd. Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
WO2011107855A2 (en) 2010-03-04 2011-09-09 Torrent Pharmaceuticals Limited Sustained release oral liquid suspension dosage form
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
US20110218209A1 (en) 2010-03-06 2011-09-08 Paul Daniel Yered Nutrient delievry drug composition
US20110230816A1 (en) 2010-03-18 2011-09-22 Tyco Healthcare Group Lp Gels for Transdermal Delivery
IT1398930B1 (it) 2010-03-24 2013-03-28 Molteni & C Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi.
CN102821791B (zh) 2010-03-30 2015-06-17 磷肌酸有限公司 透皮递送贴剂
WO2011126910A2 (en) 2010-03-30 2011-10-13 Algynomics Inc. Compositions and methods for the treatment of somatosensory disorders
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
US20110239745A1 (en) 2010-04-01 2011-10-06 Lawrence Livermore National Security, Llc Rapid Identification of Explosives Using Thin-Layer Chromatography and Colorimetric Techniques
WO2011123866A1 (en) 2010-04-02 2011-10-06 Alltranz Inc. Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
WO2011127467A1 (en) 2010-04-09 2011-10-13 Companion Diagnostics, Inc. Devices, systems, and methods for biomarker stabilization
WO2011139595A2 (en) 2010-04-27 2011-11-10 Medtronic, Inc. Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
CA2798885C (en) 2010-05-10 2014-11-18 Euro-Celtique S.A. Combination of active loaded granules with additional actives
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
FR2959935B1 (fr) 2010-05-14 2013-02-08 Ethypharm Sa Forme pharmaceutique orale alcoolo-resistante
CN101824144A (zh) 2010-05-15 2010-09-08 西北师范大学 聚乙二醇芳氧乙酸酯及其制备和作为植物生长调节剂的应用
CA3065589C (en) 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
JP2011256115A (ja) 2010-06-04 2011-12-22 Michishi Tani 自閉症の治療薬
FR2960775A1 (fr) 2010-06-07 2011-12-09 Ethypharm Sa Microgranules resistants au detournement
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
EP2588085A1 (en) 2010-06-30 2013-05-08 Upsher-Smith Laboratories, Inc. Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid
US20120141554A1 (en) 2010-07-08 2012-06-07 Wellesley Pharmaceuticals, Llc Delayed release formulation for reducing the frequency of urination and method of use thereof
AR082167A1 (es) 2010-07-14 2012-11-14 Gruenenthal Gmbh Formas de dosificacion gastrorretentivas
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
US9526600B2 (en) 2010-07-20 2016-12-27 Warsaw Orthopedic, Inc. Biodegradable stents and methods for treating periodontal disease
US20120022009A1 (en) 2010-07-21 2012-01-26 Acella Pharmaceuticals, Llc Tannate dry powder formulations
WO2012011917A1 (en) 2010-07-23 2012-01-26 Activbiotics Pharma, Llc Administration of rifalazil to immunocompromised patients
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
US20120039957A1 (en) 2010-08-13 2012-02-16 Acura Pharmaceuticals, Inc. Optimized niacin compositions in pharmaceutical products
KR101518143B1 (ko) 2010-08-13 2015-05-06 유로-셀티큐 에스.에이. 저장 안정성 제제를 제조하기 위한 결합제의 용도
FR2963889B1 (fr) 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
US8507844B2 (en) 2010-08-31 2013-08-13 Waters Technologies Corporation Techniques for sample analysis
CN101926757B (zh) 2010-09-01 2013-01-02 北京大学 一种难溶性药物的液体组合物及其制备方法
PL2611426T3 (pl) 2010-09-02 2014-09-30 Gruenenthal Gmbh Postać dawkowania zawierająca nieorganiczne sole, odporna na zgniatanie
JP5925778B2 (ja) 2010-09-02 2016-05-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング アニオン性ポリマーを含む不正使用抵抗性剤形
MX2013002293A (es) 2010-09-02 2013-05-09 Gruenenthal Gmbh Forma de dosificacion resistente a alteracion que comprende un polimero anionico.
EP2616538A4 (en) 2010-09-16 2014-03-05 Univ Cornell USE OF ADENOSINE RECEPTOR SIGNALS FOR MODULATING THE PERMEABILITY OF THE BLOOD-BRAIN BARRIER
WO2012040651A2 (en) * 2010-09-24 2012-03-29 QRxPharma Ltd. Controlled release formulations of opioids
CN103167800A (zh) 2010-10-21 2013-06-19 Rtu制药有限责任公司 即用型酮咯酸注射液
EP2444064A1 (en) 2010-10-22 2012-04-25 Meliatys Process for making multiparticulate gastroretentive dosage forms
US20120100183A1 (en) 2010-10-23 2012-04-26 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US20120202838A1 (en) 2010-11-04 2012-08-09 Abbott Laboratories Drug formulations
US20130230587A1 (en) 2010-11-10 2013-09-05 Rubicon Research Private Limited Sustained release compositions
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
AU2011336300B2 (en) 2010-12-02 2015-05-21 Adare Pharmaceuticals, Inc. Rapidly dispersing granules, orally disintegrating tablets and methods
EP2649443A2 (en) 2010-12-06 2013-10-16 Ramot at Tel-Aviv University Ltd Methods and kits for detection of drugs
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
EP2651399A2 (en) 2010-12-13 2013-10-23 Purdue Pharma LP Controlled release dosage forms
AP3815A (en) 2010-12-22 2016-09-30 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
BR112013015939A2 (pt) 2010-12-23 2020-08-04 Purdue Pharma L.P. formas farmacêuticas orais sólidas resistentes à adulteração
SG191316A1 (en) 2010-12-23 2013-07-31 Abbott Gmbh & Co Kg Solid retard formulations based on solid dispersions
US8518438B2 (en) 2011-01-14 2013-08-27 Enspire Group, Llc Highly concentrated liquid acetaminophen solutions
WO2012098281A2 (es) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Péptidos moduladores de receptores trp y sus usos
USRE47009E1 (en) 2011-02-01 2018-08-28 The Children's Hospital Of Philadelphia HDAC inhibitors and therapeutic methods using the same
MX2013009492A (es) 2011-02-17 2014-07-30 Qrxpharma Ltd Tecnologia para prevenir el abuso de formas de dosificacion solidas.
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CN102648985B (zh) 2011-02-24 2014-03-26 温州中科应急急救包有限公司 壳聚糖急救止血材料
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
JP6043733B2 (ja) 2011-02-25 2016-12-14 アリーナ ファーマシューティカルズ， インコーポレイテッド カンナビノイド受容体モジュレーター
KR101077468B1 (ko) 2011-03-04 2011-11-07 (주)차바이오앤디오스텍 안정한 경구용 속용 필름 제제
US9115133B2 (en) 2011-03-22 2015-08-25 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
DK2688556T3 (da) 2011-03-25 2015-08-03 Purdue Pharma Lp Farmaceutiske doseringsformer med kontrolleret frigivelse
BRPI1106121A2 (pt) 2011-11-25 2015-12-08 Univ Minas Gerais composições farmacêuticas contendo 11, 12-pirazolminociclina e uso para alívio de dor de origem neuropática
US20120289534A1 (en) 2011-05-11 2012-11-15 Kirax Corporation Package for improved treatment of conditions
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US9907812B2 (en) 2011-06-22 2018-03-06 Vyome Biosciences Pvt. Ltd. Conjugate-based antifungal and antibacterial prodrugs
US8623377B2 (en) 2011-06-29 2014-01-07 University Of Maryland, Baltimore Joint-homing peptides and uses thereof
HUE031251T2 (en) 2011-06-30 2017-07-28 Develco Pharma Schweiz Ag Controlled release oral dosage form containing oxycodone
EP2726065A4 (en) 2011-06-30 2014-11-26 Neos Therapeutics Lp MISS-BROKEN MEDICINAL PRODUCTS
CN102344534A (zh) 2011-07-12 2012-02-08 天津工业大学 含扑热息痛结构的聚甲基聚乙二醇丙烯酸酯及其制备方法和使用方法
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US20130028955A1 (en) 2011-07-25 2013-01-31 Gaurav Thakersi Tolia Sustained release oral matrix and methods of making thereof
US8579924B2 (en) 2011-07-26 2013-11-12 Covidien Lp Implantable devices including a mesh and a pivotable film
KR101303479B1 (ko) 2011-07-28 2013-09-06 (주)씨엘팜 가식성 필름형성 조성물 및 약물이 함유된 가식성 필름형 제제
DK2736495T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Misbrugsbestandig tablet som tilvejebringer øjeblikkelig frigivelse af lægemiddel
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
CN102389423A (zh) 2011-09-09 2012-03-28 北京阜康仁生物制药科技有限公司 一种含有布洛芬钠盐的药用组合物
ES2583132T3 (es) 2011-09-16 2016-09-19 Purdue Pharma L.P. Formulaciones de liberación inmediata resistentes a alteración
CA2847613A1 (en) 2011-09-16 2013-03-21 Purdue Pharma L.P. Tamper resistant immediate release formulations
US20140341984A1 (en) 2011-09-16 2014-11-20 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP2763664A2 (en) 2011-10-06 2014-08-13 Grünenthal GmbH Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist
CN103889456A (zh) 2011-10-18 2014-06-25 普渡制药公司 丙烯酸类聚合物制剂
JP5859664B2 (ja) 2011-10-21 2016-02-10 テウォン ファーマシューティカル カンパニー リミテッド 薬物の味がマスクされた経口用薬学組成物及びその製造方法
JP2014531031A (ja) 2011-10-21 2014-11-20 デシマドックス， エルエルシー 小分析物の定量的検出のためのポイントオブケア免疫アッセイ
KR101203186B1 (ko) 2011-10-21 2012-11-23 주식회사 대웅제약 약물의 맛이 차폐된 경구용 약학 조성물 및 그 제조 방법
US8932621B2 (en) 2011-10-25 2015-01-13 Covidien Lp Implantable film/mesh composite
US9005308B2 (en) 2011-10-25 2015-04-14 Covidien Lp Implantable film/mesh composite for passage of tissue therebetween
WO2013061161A2 (en) 2011-10-28 2013-05-02 Green Bcn Consulting Services Sl New combination therapies for treating neurological disorders
US9457024B2 (en) 2011-11-07 2016-10-04 Nektar Therapeutics Compositions, dosage forms, and co-administration of an opioid agonist compound and a non-steroidal anti-inflammatory drug
US20130122098A1 (en) 2011-11-14 2013-05-16 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
AR088875A1 (es) 2011-11-17 2014-07-16 Gruenenthal Gmbh Forma de dosis farmaceutica oral a prueba de manipulacion
WO2013077851A1 (en) 2011-11-22 2013-05-30 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
US9944985B2 (en) 2011-11-30 2018-04-17 Children's Hospital Medical Center Personalized pain management and anesthesia: preemptive risk identification and therapeutic decision support
FR2983409B1 (fr) 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
EP2787978B1 (en) 2011-12-09 2016-09-21 Purdue Pharma LP Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) and polyethylene oxide
WO2013093877A2 (en) 2011-12-23 2013-06-27 Koninklijke Philips Electronics N.V. Encapsulation system for controlled release of a bleaching agent
US9095840B2 (en) 2012-01-03 2015-08-04 The Penn State Research Foundation Nitrogen-containing activated carbon material
US9399123B2 (en) 2012-01-04 2016-07-26 Momentive Performance Materials Inc. Silicone adhesive compositions
WO2013119231A1 (en) 2012-02-09 2013-08-15 Tris Pharma, Inc. Abuse resistant opioid drug - ion exchange resin complexes having hybrid coatings
GB201202223D0 (en) 2012-02-09 2012-03-28 Randox Lab Ltd Immunoassay for pyrrolidinophenones
CN103040829B (zh) 2012-02-17 2015-02-11 北京人福军威医药技术开发有限公司 含有高乌甲素和羟考酮的药物组合物
US20130225625A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013128447A1 (en) 2012-02-28 2013-09-06 Sipnose Ltd. Nasal delivery device
US20130225412A1 (en) 2012-02-28 2013-08-29 Soroush Sardari Lodriche Silicon nanocarrier for delivery of drug, pesticides and herbicides , and for waste water treatment
PE20142320A1 (es) 2012-03-02 2015-01-16 Rhodes Pharmaceuticals Lp Formulaciones de liberacion inmediata resistentes a la manipulacion
US10383835B2 (en) 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
SI2825208T1 (sl) 2012-03-14 2017-10-30 Levicept Ltd. P75ntr nevrotrofin vezavni protein za terapevtsko rabo
WO2013151638A1 (en) 2012-04-06 2013-10-10 Indus Pharmaceuticals, Inc. Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
US9687445B2 (en) 2012-04-12 2017-06-27 Lts Lohmann Therapie-Systeme Ag Oral film containing opiate enteric-release beads
CN104254323A (zh) 2012-04-13 2014-12-31 旗帜药物胶囊公司 含有片剂和液体或半固体填充剂的软弹性胶囊及其制备方法
US20130280176A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate Release Pharmaceutical Compositions with Abuse Deterrent Properties
CA2864738C (en) 2012-04-18 2017-07-18 Mallinckrodt Llc Immediate release, abuse deterrent pharmaceutical compositions
MX362357B (es) 2012-04-18 2019-01-14 Gruenenthal Gmbh Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
EP2846755A1 (en) 2012-05-09 2015-03-18 SiO2 Medical Products, Inc. Saccharide protective coating for pharmaceutical package
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2013171146A1 (en) 2012-05-15 2013-11-21 Lts Lohmann Therapie-Systeme Ag Oral film containing enteric release opiate resinate
WO2013175511A1 (en) 2012-05-24 2013-11-28 V.B. Medicare Pvt. Ltd. Taste masked pharmaceutical compositions
JP2013249458A (ja) 2012-06-04 2013-12-12 Hitachi Chemical Co Ltd 封止用エポキシ樹脂成形材料及び電子部品装置
DE102012105512A1 (de) 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
US10071088B2 (en) 2012-06-26 2018-09-11 Precondit, Llc Anti-nausea drug combinations
CN104582733B (zh) 2012-06-27 2017-07-04 美蒂森 用于疏水性组合物的可生物降解的药物释放***
BR112015000150A2 (pt) * 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
US20140045801A1 (en) 2012-08-09 2014-02-13 Mylan Inc. Pramipexole transdermal delivery for severe headaches
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
CA2791206A1 (en) 2012-09-28 2014-03-28 Pharmascience Inc. Abuse deterrent pharmaceutical formulation
US10987365B2 (en) 2012-10-01 2021-04-27 Gm Pharmaceuticals, Inc. Compositions and methods for the treatment of pain
WO2014059512A1 (en) 2012-10-15 2014-04-24 Isa Odidi Oral drug delivery formulations
CN103070840A (zh) 2012-10-31 2013-05-01 北京正大绿洲医药科技有限公司 盐酸羟考酮缓释滴丸及其制备方法
CA3179312A1 (en) * 2013-03-15 2014-09-18 Vapogenix, Inc. Analgesic compositions comprising halogenated volatile compounds
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US20160199369A1 (en) 2013-08-12 2016-07-14 Pharmaceutical Manufacturing Research Services, Inc. Extruded Immediate Release Abuse Deterrent Pill
CN103637998B (zh) 2013-12-09 2016-04-06 韩彬 包含羟考酮和罗通定的缓释片剂
CN103637987B (zh) 2013-12-09 2015-12-02 韩彬 羟考酮的液体药物组合物
US10772841B2 (en) 2014-04-07 2020-09-15 Patheon Softgels Inc. Opioid abuse-deterrent controlled release formulations

Also Published As

Publication number Publication date
CA2955229A1 (en) 2016-01-21
WO2016010771A1 (en) 2016-01-21
AU2015290098B2 (en) 2018-11-01
AU2015290098A1 (en) 2017-01-19
JP6371463B2 (ja) 2018-08-08
US20170340574A1 (en) 2017-11-30
EP3169315B1 (en) 2020-06-24
JP2017521448A (ja) 2017-08-03
EP3169315A1 (en) 2017-05-24
JP2018197241A (ja) 2018-12-13
CA2955229C (en) 2020-03-10
EP3169315A4 (en) 2018-03-21
US9707184B2 (en) 2017-07-18
ES2809458T3 (es) 2021-03-04
AU2019200026A1 (en) 2019-01-24
US20160015650A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3096741T3 (da) Fremgangsmåde til fremstillingen af hybridosomer
DK3140008T3 (da) Hurtigtvirkende insulinsammensætninger
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3174858T3 (da) Fremgangsmåde til fremstilling af pyrazoler
DK3232872T3 (da) System til tilberedning af drikkevarer
DK3215173T3 (da) Glycopeptidsammensætninger
DK3040326T3 (da) Haloolefin-baseret sammensætning
MA41107A (fr) Compositions anti-cancéreuses
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3171700T3 (da) Infusionsanlæg
DK3233813T3 (da) Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser
FR3024363B1 (fr) Composition thermogelifiable
DK3277690T3 (da) Spirocykliske forbindelser
DK3177931T3 (da) Fremgangsmåde til bestemmelse af stoffers evne til at binde til analytaktive steder
CL2017000639A1 (es) Composición
DK3126791T3 (da) Doseringsanordning
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
MA41266A (fr) Cataplasme
DK3230929T3 (da) Forbedringer til tælleranordninger
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3200827T3 (da) Sammensætninger
DK3217964T3 (da) Sammensætning